tirzepatide updates Important Update: Compounded Phasing Out! Breaking News: OFA Challenges FDA

After the SELECT trial cardiovascular indication for Wegovy (FDA approved March 2024) and the SURMOUNT-OSA approval for Zepbound (December 2024), Aetna added separate coverage pathways for those medical indications, which often bypass the obesity carve-outs

Researchers needing this compound would need to source it from alternative retatrutide suppliers while potentially maintaining Simple Peptide as their tirzepatide and semaglutide source

It analyzes pathway-level variants (GLP1R (rs6923761), GIPR (rs1800437), FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction

Bottom line: While appendicitis is a serious condition, it is a very rare occurrence among GLP-1 users

As a brand-name prescription drug, Mounjaro isnt cheap

The third and differentiating layer is glucagon receptor agonism